ORIGINAL ARTICLE

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study

Chihiro Takahashi,¹ Yuko Kaneko,¹ Yutaka Okano,² Hiroaki Taguchi,² Hisaji Oshima,³ Keisuke Izumi,^{1,3} Kunihiro Yamaoka,¹ Tsutomu Takeuchi¹

To cite: Takahashi C, Kaneko Y, Okano Y, *et al.* Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. *RMD Open* 2017;**3**:e000363. doi:10.1136/rmdopen-2016-000363

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/rmdopen-2016-000363>).

Received 12 September 2016
Revised 4 November 2016
Accepted 4 December 2016

CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Tsutomu Takeuchi;
tsutake@keio.jp

ABSTRACT

Objective: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA).

Methods: 79 MTX-naïve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed.

Results: Dose escalation of MTX resulted in increased MTX-PG concentrations and a decrease in the mean Disease Activity Score in 28 joints (DAS28). A significant association was observed between total MTX-PG concentrations and Δ DAS28 at week 12 ($\beta=-0.013$, $p=0.003$) and at week 24 ($\beta=-0.014$, $p=0.003$). The maximum MTX-PG levels were significantly higher in patients presenting with elevated transaminases (≥ 100 IU/L) than in those without (146 vs 106 nmol/L, $p=0.009$). Receiver operating characteristic curve analysis revealed that a total MTX-PG concentrations of 83 nmol/L at week 12 was the threshold for a DAS28 improvement of ≥ 1.2 at week 24, and 105 nmol/L was the threshold for transaminases of ≥ 50 IU/L and 131 nmol/L for transaminases of ≥ 100 IU/L. MTX-PG concentrations were strongly influenced by body mass index and a serum albumin level.

Conclusions: MTX-PG concentrations are a useful biomarker in MTX therapy, in terms of efficacy and safety.

INTRODUCTION

Methotrexate (MTX) is the mainstay of disease-modifying anti-rheumatic drug (DMARD) therapy. It is widely used to treat rheumatoid arthritis (RA) because of its

Key messages

What is already known about this subject?

- Risk factors underlying the interpatient variability in the response to methotrexate (MTX) in patients with rheumatoid arthritis have been unclear.
- While plasma MTX concentrations fall below pharmacologically effective levels rapidly, MTX-polyglutamates (MTX-PGs) retained within the cells for a period of time might be a potential biomarker associated with response to MTX.

What does this study add?

- This long-term multicentre prospective study assessed the relationship between the dynamics of intraerythrocyte MTX-PG concentrations and the efficacy and adverse effects of MTX in patients with rheumatoid arthritis.

How might this impact on clinical practice?

- Monitoring MTX-PGs could optimise treatment response while minimising liver injury in the treatment with MTX.
- The body mass index and the serum albumin level affected MTX-PG concentrations.

marked efficacy and acceptable side effect profile.¹ However, a number of patients have a poor response despite dose escalation, or experience adverse events resulting in dose restriction or treatment cessation. At present, the mechanisms and risk factors underlying the interpatient variability in the response to MTX have not been established. However, the amount of MTX or MTX metabolites in the body could be a major determinant of its effect.

MTX is transported into cells via a reduced folate carrier, where it is converted by

folylpolyglutamate synthase into glutamate-chained MTX. It is retained within the cells for a period of time after its elimination from the plasma. Depending on the number of conjugated glutamates, MTX-polyglutamates (MTX-PGs) can be present as MTX-PG1 through 5. MTX-PGs inside the cells increase the inhibition of de novo purine synthesis and promote the accumulation of adenosine, thereby exerting immunosuppressive and anti-inflammatory effects.²⁻⁴

Plasma MTX concentrations fall below pharmacologically effective levels rapidly.⁵ Therefore, they are unreliable for predicting the efficacy or toxicity of MTX in patients with RA.⁶⁻¹² In contrast, MTX-PG concentrations in erythrocytes have been identified as a potentially promising biomarker associated with response to MTX in patients with RA and juvenile idiopathic arthritis.¹²⁻¹⁷ However, the majority of these studies employed a cross-sectional design, and reported conflicting results on the efficacy and limited findings on the safety of MTX in relation to MTX-PG concentrations.

The aim of this long-term multicentre prospective study was to clarify the association between the dynamics of intraerythrocyte MTX-PG concentrations and the efficacy and adverse effects of MTX in patients with RA.

METHODS

Study protocol and patients

The MAGIK (methotrexate as an anchor drug in Japanese rheumatoid arthritis monitored by erythrocyte PG concentrations at the Keio Rheumatology Expert Meeting) study, which was a 76-week long multicentre prospective study, started in December 2012. The medical ethics committee at each study site approved the protocol prior to study initiation, and all patients gave written informed consent before enrolment. This study was registered with the University Hospital Medical Information Network (UMIN000008514).

We enrolled patients in whom RA had been diagnosed according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.¹⁸ These patients also had to have active disease (Disease Activity Score in 28 joints (DAS28) > 3.2), be naïve to MTX or biological agent therapy, and be scheduled to start MTX treatment for their RA. Patients who were contraindicated to MTX, had a desire to bear a child, or had serious complications were excluded.

The study protocol specified the dose-escalation procedure for MTX, as well as the time points for performing clinical assessments including disease activity and adverse events and measuring MTX-PG concentrations. MTX was started at a dose of 8 mg/week with 5 mg/week folic acid, and was increased by 4 mg every 4 weeks until 16 mg/week, the maximum dose allowed in Japan, had been reached. Adding other DMARDs during the study was not allowed. This protocol was followed unless

the patient achieved remission or experienced relevant adverse events. The dose could be decreased if adverse events occurred. The patients' clinical and biochemical parameters were assessed at baseline and at weeks 4, 8, 12, 24, 36, 52 and 76 of the study.

Clinical parameters

Data on patient demographics and clinical characteristics were obtained. This included age, sex, duration of arthritic symptoms, smoking status, body mass index (BMI), DAS28, Health Assessment Questionnaire Disability Index score (HAQ-DI), rheumatoid factor, anti-cyclic citrullinated peptide antibody, estimated glomerular filtration rate (eGFR) calculated with the Cockcroft-Gault formula, aspartate transaminase (AST) levels, alanine transaminase (ALT) levels and blood cell counts. Hepatotoxicity was defined as AST or ALT > 50 IU/L, and leucopenia was defined as white cell count < 3000/μL. Outcome measures for effectiveness of MTX were ΔDAS28, EULAR good response,¹⁹ DAS28 remission²⁰ and ΔHAQ-DI.

MTX-PG concentrations

To measure the MTX-PG concentrations, blood samples were collected in EDTA tubes at prespecified clinical assessment visits. The EDTA tube was centrifuged for 5 min at 3000 rpm at 4°C. The cell pellet was collected and centrifuged again after the addition of isotonic saline. The resulting packed red blood cells were stored at -80°C. These samples were air-shipped under dry ice to Exagen Diagnostics (Vista, California, USA), and the MTX-PGs (MTX-PG1, MTX-PG2, MTX-PG3, MTX-PG4 and MTX-PG5) were measured using a liquid chromatography-electrospray ionisation tandem mass spectrometry-based assay as previously described.²¹ The total MTX-PGs, or the sum of MTX-PG1 through MTX-PG5, was used in the analysis.

Statistical analysis

The comparison of proportions and correlations between groups was tested with Student's t-test, χ^2 test, Mann-Whitney U-test, Spearman's correlation coefficient, and one-way analysis of variance, in accordance with the type of variable. Cross-sectional analyses of the association of MTX-PGs with the ΔDAS28 were performed with a linear mixed model with correction by potential confounders including age, non-steroidal anti-inflammatory drug (NSAID) use, the use of other DMARDs, glucocorticoid use, smoking status and eGFR. Cut-off MTX-PG concentrations with optimal sensitivity and specificity for predicting the decrease in DAS28 of more than 1.2, or the increase in transaminases of ≥ 50 or 100 IU/L, was determined using receiver operating characteristic (ROC) curves. A two-sided statistical test of no difference at the 5% significance level was used. All statistical analyses were performed using SPSS V.23.0 (SPSS, Chicago, Illinois, USA).

RESULTS

Patient characteristics

A total of 79 patients were included in the study. Table 1 shows the baseline characteristics of the patients enrolled. The mean age was 56.7 years, and the majority of patients were female (86%). The mean BMI was 21.9 kg/m², which was around the average for Japanese individuals. The mean DAS28 was 4.0 at baseline.

Pharmacokinetics of MTX-PG in erythrocytes and disease activity

Figure 1A shows the pharmacokinetics of the total MTX-PGs and fractions of MTX-PGs in erythrocytes with the mean dose of MTX from baseline through 76 weeks. MTX-PGs were measured in 79 patients at week 4, 78 patients at week 8, 76 patients at week 12, 51 patients at week 24, 43 patients at week 36, 37 patients at week 52, and 35 patients at week 76. The attrition was due to various patient-related factors, including 2 moving house, 3 missing a blood test, 9 being lost to follow-up, 5 to adverse events, 23 to use of biological agents, or 2 withdrawing consent. Total MTX-PG values increased steadily with MTX dose-escalation and plateaued after 12 weeks at ~90 nmol/L on 10.5 mg/week of MTX. The main fractions of MTX-PGs were MTX-PG1 and MTX-PG2, followed by MTX-PG3. MTX-PG4 and MTX-PG5 were nearly undetectable throughout the 76 weeks.

Figure 1B demonstrates the mean DAS28 which decreased from 4.0 at baseline to 3.3 at week 4, 2.7 at week 8, 2.6 at week 12, 2.0 at week 24, 1.9 at week 36, 1.7 at week 52, and to 1.5 at week 76 ($p < 0.05$ at all time points compared with the baseline).

Table 1 Demographic and clinical characteristics

Characteristics (N=79)	Mean (SD)
Age (year)	56.7 (14.7)
Woman (n, %)	68 (86)
Body mass index	21.9 (3.3), N=74
Current smoker (n, %)	19 (24)
Symptom duration before MTX start (month)	2.2 (5.7)
Anti-CCP positive (n, %)	53 (67)
RF positive (n, %)	66 (85)
DAS28	4.0 (1.1)
HAQ-DI	0.894 (1.009)
AST (IU/mL)	19 (5)
ALT (IU/mL)	16 (8)
eGFR (mL/min)	88 (26)
Other DMARDs use (n, %)	7 (9)
Glucocorticoid use (n, %)	6 (8)
NSAID use (n, %)	27 (34)

ALT, alanine transaminase; Anti-CCP, anti-cyclic citrullinated peptide; AST, aspartate transaminase; DAS28, Disease Activity Score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; eGFR, estimated glomerular filtration rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; NSAID, non-steroid anti-inflammatory drug; RF, rheumatoid factor.

Association of MTX-PG concentration with clinical effectiveness

Table 2 shows the results of cross-sectional analyses with a linear mixed modelling for association between MTX-PG levels with Δ DAS28 at the corresponding visit. A significant association with Δ DAS28 was observed for MTX-PG3 ($\beta = -0.035$; SE=0.017; $p = 0.04$) at week 8; MTX-PG1 ($\beta = -0.025$; SE=0.007; $p = 0.000$), MTX-PG2 ($\beta = -0.035$; SE=0.011; $p = 0.002$) and total MTX-PG ($\beta = -0.013$; SE=0.004; $p = 0.003$) at week 12; MTX-PG1 ($\beta = -0.026$; SE=0.009; $p = 0.005$), MTX-PG2 ($\beta = -0.027$; SE=0.012; $p = 0.03$), MTX-PG3 ($\beta = -0.028$; SE=0.014; $p = 0.04$) and total MTX-PG ($\beta = -0.014$; SE=0.004; $p = 0.003$) at week 24; and for MTX-PG3 ($\beta = -0.03$; SE=0.015; $p = 0.04$) at week 36. Furthermore, MTX-PG levels at week 12, the time when the concentrations reached a plateau, were associated with Δ DAS28 at weeks 24 and 36; MTX-PG1 ($\beta = -0.025$; SE=0.010; $p = 0.01$), MTX-PG2 ($\beta = -0.067$; SE=0.013; $p = 0.000$), MTX-PG3 ($\beta = -0.039$; SE=0.018; $p = 0.04$) and total MTX-PG ($\beta = -0.018$; SE=0.004; $p = 0.001$) at week 24; MTX-PG1 ($\beta = -0.031$; SE=0.008; $p = 0.001$), MTX-PG2 ($\beta = -0.051$; SE=0.016; $p = 0.002$) and total MTX-PG ($\beta = -0.016$; SE=0.005; $p = 0.001$) at week 36.

The associations of MTX-PG concentrations with other outcome measures including EULAR good response, DAS28 remission and Δ HAQ-DI are tabulated in tables 3 and 4. At weeks 12 and 24, MTX-PG concentrations were significantly higher in the patients who achieved EULAR good response or DAS28 remission than in those who did not. Δ HAQ-DI were associated with MTX-PG concentrations at weeks 24 and 36 by a linear mixed modelling.

ROC analysis was used to determine the cut-off concentrations of total MTX-PGs at week 12 needed to produce an improvement of >1.2 in DAS28 at week 24 (figure 1C). A total MTX-PG concentration of ≥ 83.3 nmol/L could discriminate between patients with a DAS28 improvement of ≥ 1.2 and those without; the area under the curve (AUC) for this was 0.72 (95% CI 0.57 to 0.87, $p = 0.02$).

Adverse events

Over a period of 76 weeks, 27 patients (34.2%) reported 46 instances of adverse events. Twenty patients (25.3%) presented with gastrointestinal symptoms, including nausea and stomatitis; 20 (25.3%) with hepatotoxicity (defined as AST or ALT ≥ 50 IU/L, the same patients with ALT ≥ 50 IU/L in consequence); 2 (2.5%) with leucopenia; 1 (1.3%) with hair loss; 1 (1.3%) with *Pneumocystis jirovecii* pneumonia; 1 (1.3%) with cryptococcal pneumonia; and 1 (1.3%) with malignancy (gastric cancer). The last three events were deemed to be serious adverse events.

Among the 20 patients who developed hepatotoxicity, 12 had transaminase levels exceeding 100. The maximum total MTX-PG levels were 105.6 nmol/L in patients without hepatotoxicity, 119.5 nmol/L in those with $50 \leq \text{AST/ALT} < 100$, and 146.3 nmol/L in those with

Figure 1 MTX-PG concentrations and efficacy. (A) Pharmacokinetics of MTX-PG concentrations with the mean MTX dose; (B) DAS28 and (C) cut-off values at week 12 for Δ DAS28 > 1.2 at week 24. * $p < 0.05$. AUC, area under the curve; DAS28, Disease Activity Score for 28 joints; MTX-PG, methotrexate polyglutamate.

Table 2 Cross-sectional analysis of MTX-PG concentrations and Δ DAS28 with a linear mixed model

	Week 4	Week 8	Week 12	Week 24	Week 36	Week 52	Week 76
MTX-PG1	0.018 (0.011) p=0.11	-0.003 (0.008) p=0.68	-0.025 (0.007)* p=0.000	-0.026 (0.009)* p=0.005	-0.013 (0.010) p=0.022	-0.008 (0.015) p=0.59	0.009 (0.013) p=0.49
MTX-PG2	0.018 (0.016) p=0.27	-0.002 (0.013) p=0.86	-0.035 (0.011)* p=0.002	-0.027 (0.012)* p=0.03	-0.023 (0.016) p=0.15	-0.013 (0.017) p=0.45	0.021 (0.022) p=0.35
MTX-PG3	0.019 (0.026) p=0.48	-0.035 (0.017)* p=0.04	-0.023 (0.013) p=0.07	-0.028 (0.014)* p=0.04	-0.030 (0.015)* p=0.04	-0.006 (0.020) p=0.76	0.005 (0.022) p=0.83
Total MTX-PG	0.008 (0.006) p=0.19	-0.003 (0.005) p=0.41	-0.013 (0.004)* p=0.003	-0.014 (0.004)* p=0.003	-0.009 (0.005) p=0.09	-0.005 (0.007) p=0.43	0.006 (0.007) p=0.41

Upper: β , SE.

Lower: p.

* $p < 0.05$.

DAS28, Disease Activity Score for 28 joints; MTX-PG, methotrexate polyglutamate.

AST/ALT ≥ 100 ($p = 0.009$, figure 2A). ROC analysis determined the cut-off value of MTX-PG concentrations for AST/ALT elevation ≥ 50 IU/L to be 105.4 nmol/L with an AUC of 0.67 (95% CI 0.52 to 0.81, $p = 0.03$,

figure 2B), and that for AST/ALT ≥ 100 IU/L to be 131.0 nmol/L (95% CI 0.50 to 0.93, $p = 0.04$, figure 2C). Of note, NSAIDs use and other DMARDs use were not different between the patients with AST/ALT ≥ 50 IU/L

Table 3 Associations of MTX-PG concentrations with EULAR good response, DAS28 remission and Δ HAQ-DI

	N	MTX-PG1 (nmol/L)	p Value	MTX-PG2 (nmol/L)	p Value	MTX-PG3 (nmol/L)	p Value	Total MTX-PG (nmol/L)	p Value
Week 4									
Remission (+)	23	27.1	0.51	11.8	0.58	3.1	0.75	41.3	0.48
Remission (−)	56	28.9		12.9		3.4		44.8	
Good response (+)	18	27.9	0.85	14.6	0.19	5.1	0.46	46.6	0.50
Good response (−)	61	28.5		11.9		4.8		42.9	
Δ HAQ, β (SE)	79	−0.002 (0.006)	0.68	0.004 (0.009)	0.49	0.003 (0.014)	0.7	−0.002 (0.003)	0.95
Week 8									
Remission (+)	33	40.7	0.25	22.8	8.3	10.4	0.40	71.2	0.85
Remission (−)	45	36.9		23.3		9.1		72.3	
Good response (+)	33	38.8	0.97	22.0	0.39	10.4	0.52	71.2	0.85
Good response (−)	45	39.0		23.8		9.4		72.3	
Δ HAQ, β (SE)	78	0.001 (0.005)	0.11	0.002 (0.008)	0.24	−0.011 (0.011)	0.29	−0.000 (0.003)	0.93
Week 12									
Remission (+)	46	50.4	0.02*	30.5	0.14	16.9	0.87	97.3	0.09
Remission (−)	30	40.6		26.7		16.6		84.3	
Good response (+)	39	51.1	0.007*	32.2	0.004*	18.8	0.08	101.1	0.001*
Good response (−)	37	40.1		24.9		14.6		75.9	
Δ HAQ, β (SE)	76	−0.009 (0.005)	0.08	−0.005 (0.008)	0.05	−0.011 (0.008)	0.23	−0.004 (0.003)	0.11
Week 24									
Remission (+)	35	48.7	0.03*	34.6	0.02*	24.7	0.09	109.1	0.001*
Remission (−)	14	34.9		23.2		17.4		66.4	
Good response (+)	37	35.2	0.05*	33.9	0.04*	23.4	0.50	102.1	0.11
Good response (−)	12	27.9		23.4		20.3		80.8	
Δ HAQ, β (SE)	49	−0.015 (0.006)	0.02*	−0.018 (0.008)	0.04*	−0.019 (0.010)	0.07	−0.008 (0.003)	0.02*
Week 36									
Remission (+)	37	46.4	0.18	30.2	0.32	21.7	0.48	98.8	0.22
Remission (−)	5	33.7		24.3		17.6		75.6	
Good response (+)	33	46.1	0.46	30.4	0.41	22.6	0.16	99.3	0.25
Good response (−)	9	40.5		26.5		16.2		83.9	
Δ HAQ, β (SE)	42	−0.012 (0.009)	0.19	−0.020 (0.014)	0.17	−0.038 (0.016)	0.03*	−0.014 (0.006)	0.03*
Week 52									
Remission (+)	32	39.8	0.07	27.6	0.72	16.8	0.18	84.0	0.13
Remission (−)	4	55.9		30.1		25.0		111.0	
Good response (+)	28	39.9	0.24	27.0	0.46	17.7	0.08	84.2	0.31
Good response (−)	8	47.8		30.8		18.0		96.7	
Δ HAQ, β (SE)	36	−0.026 (0.014)	0.07	−0.016 (0.017)	0.33	−0.006 (0.020)	0.76	−0.005 (0.007)	0.43

Continued

Table 3 Continued

	N	MTX-PG1 (nmol/L)	p Value	MTX-PG2 (nmol/L)	p Value	MTX-PG3 (nmol/L)	p Value	Total MTX-PG (nmol/L)	p Value
Week 76									
Remission (+)	31	45.4	0.99	26.2	0.51	17.5	0.99	89.3	0.72
Remission (–)	3	45.5		30.2		17.4		93.1	
Good response (+)	28	44.5	0.51	26.1	0.51	17.8	0.68	88.6	0.55
Good response (–)	6	49.5		29.0		15.8		94.7	
ΔHAQ, β (SE)	34	–0.008 (0.011)	0.49	0.000 (0.017)	0.98	–0.002 (0.016)	0.90	–0.002 (0.006)	0.72

*p<0.05.

DAS28, Disease Activity Score for 28 joints; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; MTX-PG, methotrexate polyglutamate.

Table 4 Correlations of baseline factors with total MTX-PGs at weeks 12 and 24

	12 weeks	24 weeks
Age	0.008	–0.011
	0.94	0.94
Body weight	–0.205	–0.305
	0.08	0.03*
Body mass index	–0.318	–0.422
	0.006*	0.002*
White blood count	0.192	0.239
	0.10	0.09
Red blood count	–0.116	–0.137
	0.32	0.34
Serum albumin	–0.146	–0.364
	0.22	0.01*
eGFR	–0.038	0.061
	0.75	0.67

Upper: p.

Lower: p.

*p<0.05.

eGFR, estimated glomerular filtration rate; MTX-PG, methotrexate polyglutamates.

and those without (20% vs 39%, p=0.09 for NSAIDs use; 10% vs 9%, p=0.85 for other DMARDs use).

Factors affecting MTX-PG concentrations

To identify the individual patient factors affecting MTX-PG concentrations at weeks 12 and 24, correlation analyses of total MTX-PG concentrations with baseline patient characteristics including age, body weight, BMI, white cell count, red cell count, albumin level and eGFR were performed. The baseline BMI strongly affected total MTX-PGs at week 12 ($p=-0.318$, $p=0.006$) and week 24 ($p=-0.422$, $p=0.002$). Similar trends were observed for body weight ($p=-0.305$, $p=0.03$) and serum albumin ($p=-0.422$, $p=0.002$) at week 24.

In order to verify the influence of BMI on the concentrations of MTX-PG, we divided 75 patients (no BMI data available in four patients) into three groups according to the BMI categories defined by the WHO: 12 underweight patients ($BMI < 18.5 \text{ kg/m}^2$), 52 normal weight patients ($18.5 \leq BMI < 25.0 \text{ kg/m}^2$) and 11 overweight patients ($BMI \geq 25.0 \text{ kg/m}^2$). The total MTX-PG concentrations differed significantly among the three BMI groups (figure 3A). At week 24, the concentrations were found to be 151.6 nmol/L in the underweight group at 10.7 mg/week of MTX, 92.1 nmol/L in the normal group at 10.9 mg/week, and 65.6 nmol/L in the overweight group at 9.1 mg/week ($p=0.001$), while the ΔDAS28 at week 24 was comparable between the groups (–2.0 in the underweight group vs –1.7 in the normal group vs –1.8 in the overweight group, $p=0.77$, figure 3B). Elevated transaminase levels ($AST/ALT \geq 100 \text{ IU/L}$) were observed in 33.3% of the underweight group, 15.4% of the normal weight group and none of the overweight group ($p=0.07$, figure 3C).

Figure 2 MTX-PG concentrations and hepatotoxicity. (A) Maximum MTX-PG concentrations among groups with or without hepatotoxicity; (B) cut-off values of total MTX-PG concentration for AST/ALT ≥ 50 and (C) cut-off values of total MTX-PG concentration for AST/ALT ≥ 100 . * $p < 0.05$. ALT, alanine transaminase; AST, aspartate transaminase; AUC, area under the curve; DAS28, Disease Activity Score for 28 joints; MTX-PG, methotrexate polyglutamate.

Figure 3 MTX-PG concentrations and BMI. (A) MTX-PG concentrations in the three groups divided according to the BMI category; (B) decrease in DAS28 in the three groups and (C) the frequency of AST/ALT ≥ 100 . * $p < 0.05$. ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DAS28, Disease Activity Score for 28 joints; MTX-PG, methotrexate polyglutamate.

DISCUSSION

This prospective longitudinal cohort study revealed the utility of MTX-PG concentrations in assessing the efficacy and toxicity of MTX in patients with RA. We concluded that total MTX-PG concentrations between 83 and 105 nmol/L could be optimal for maximising the efficacy of MTX while minimising its toxicity in patients with RA. In addition, we have also identified the significant effect BMI has on MTX-PG concentrations.

Associations between MTX-PG concentrations in erythrocytes and disease activity in patients with RA have been investigated in several studies.^{12–18 21–24} Most of these studies have shown that higher MTX-PG levels were associated with lower disease activity, or that MTX-PG levels were significantly higher in patients responsive to MTX. Three longitudinal studies showed that an increase in MTX-PG concentrations was associated with a decrease in DAS28 scores.^{16 21 22} The results of our longitudinal study in MTX-naïve Japanese patients with RA are consistent with those of previous studies, and we have added to the body of knowledge by showing that 83 nmol/L could be the threshold for a DAS28 improvement of ≥ 1.2 by MTX. Although the relatively low mean DAS28 of 4.0 at baseline might be interpreted cautiously, we believe our results have provided new insights into the usage of MTX.

Little is known about the relationship of MTX-PGs and the safety of MTX. There have been a few reports indicating a relationship between adverse events and high MTX-PG3 to five levels in patients with juvenile idiopathic arthritis or inflammatory bowel disease.^{25 26} However, none of the MTX-PGs fractions have been linked to adverse events in patients with RA.²¹ Our findings have demonstrated the clear correlation between the MTX-PG levels and hepatotoxicity by showing that higher MTX-PG concentrations could result in higher transaminase levels. Although the maximum dose of MTX approved in Japan is 16 mg/week, the mean MTX dose used in actuality remains ~ 12 mg/week owing to the predisposition of Japanese patients to adverse events.²⁷ The frequent hepatotoxicity observed in our study clarified the relationship between MTX-PG concentrations and liver injury. Liquid chromatography-electrospray ionisation tandem mass spectrometry used to measure MTX-PG levels may be disadvantageous in the cost and the practicality at the moment; nevertheless, monitoring MTX-PG concentrations can be helpful in clinical practice.

Interestingly, despite the dosages of MTX used being largely similar, the MTX-PG concentrations in our patients were markedly higher than those observed in other studies from Europe or the USA. Our samples were evaluated by Exagen using the exact same method reported by Dervieux *et al*,²¹ who found that the total MTX-PGs at week 20 were around 65 nmol/L in patients with RA in the USA at 13.4 mg/week of MTX. In contrast, our cohort, which comprised Japanese patients with RA, demonstrated MTX-PG concentrations of 94 nmol/L at 10.3 mg/week of MTX at week 24. The difference in MTX-PG concentrations could potentially be ascribed to the differences in physical frames. We found that BMI strongly affected MTX-PG concentrations, and that total MTX-PG concentrations were much higher in underweight patients despite the similar MTX dose. MTX-related pharmacogenomics may be another possibility. Several studies have indicated that MTX-PG concentrations may be influenced by polymorphisms in the

genes encoding the enzymes and transporters involved in the import and export of MTX/MTX-PGs, and ethnic variations have been reported to influence the frequencies of these polymorphisms.^{28–30} Further studies are needed to investigate these polymorphisms in Japanese patients.

In conclusion, this study suggests that maintaining the MTX-PG concentrations in erythrocytes at ~ 80 – 100 nmol/L could optimise treatment response while minimising liver injury in the treatment of RA with MTX. As such, monitoring MTX-PG concentrations can be helpful in clinical practice.

Author affiliations

¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

²Department of Internal Medicine and Center for Arthritis and Rheumatic Disease, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan

³Department of Connective Tissue Diseases, Tokyo Medical Center, National Hospital Organization, Tokyo, Japan

Acknowledgements The authors would like to thank Ms Harumi Kondo and Ms Mayumi Ota for their assistance in the acquisition of clinical information.

Contributors CT, YK and TT designed the study and analysed and interpreted the data. CT, YK, YO, HT, HO, KI and KY were involved in collecting data and managing the clinical research sites. All authors were involved in the writing of the manuscript and have approved the final version.

Competing interests YK has received lecture fees from Abbvie, Eisai Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, Janssen and UCB. HO has received lecture fees from Astellas Pharma, Asahi Kasei, Takeda Pharmaceutical, Bristol Myers Squibb, MSD LLC, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma Corporation and DS Pharma Biomedical Co. KY has received consulting fees and speaking fees from Pfizer, Chugai Pharma, Mitsubishi-Tanabe Pharma, Takeda Industrial Pharma, GlaxoSmithKline, Nippon Shinyaku, Eli Lilly, Janssen Pharma, Eisai Pharma, Astellas Pharma and Acterlion Pharmaceuticals. TT has received research grants and lecture fees from Abbvie, Astra Zeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Novartis, Takeda Pharmaceutical, Abbott Japan Co., Astellas Pharma, Daiichi Sankyo, Pfizer, Sanofi-Aventis, Santen Pharmaceutical, Teijin Pharma, Asahikasei Pharma Corp., SymBio Pharmaceuticals, Celtrion, Nipponkayaku Co., Eli Lilly Japan K.K. and Taisho Toyama Pharmaceutical.

Patient consent Obtained.

Ethics approval Keio University School of Medicine, Ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Smolen JS, Landewé R, Breedveld FC, *et al*. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014;73:492–509.
- Dervieux T, Brenner TL, Hon YY, *et al*. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. *Blood* 2002;100:1240–7.

3. Morabito L, Montesinos MC, Schreiber DM, *et al.* Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5-nucleotidase-mediated conversion of adenosine nucleotides. *J Clin Invest* 1998;101:295–300.
4. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. *J Clin Invest* 1993;92:2675–82.
5. Godfrey C, Sweeney K, Miller K, *et al.* The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. *Br J Clin Pharmacol* 1998;46:369–76.
6. Hiraga Y, Yuhki Y, Itoh K, *et al.* Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. *Mod Rheumatol* 2004;14:135–42.
7. Lebbe C, Beyeler C, Gerber NJ, *et al.* Intraindividual variability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis. *Ann Rheum Dis* 1994;53:475–7.
8. Ravelli A, Di Fuccia G, Molinaro M, *et al.* Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. *J Rheumatol* 1993;20:1573–7.
9. Hornung N, Ellingsen T, Attermann J, *et al.* MTX correlate to plasma concentrations and clinical efficacy. *J Rheumatol* 2008;35:1709–15.
10. Dalrymple JM, Stamp LK, O'Donnell JL, *et al.* Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 2008;58:3299–308.
11. Bannwarth B, Pehourcq F, Schaeferbeke T, *et al.* Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. *Clin Pharmacokinet* 1996;30:194–210.
12. Hornung N, Ellingsen T, Attermann J, *et al.* Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. *J Rheumatol* 2008;35:1709–15.
13. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. *Clin Exp Rheumatol* 1999;17:313–20.
14. Dervieux T, Furst D, Lein DO, *et al.* Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. *Ann Rheum Dis* 2005;64:1180–5.
15. Hohl EL, Jilma B, Erlacher L, *et al.* A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. *Clin Exp Rheumatol* 2012;30:156–63.
16. de Rotte MC, den Boer E, de Jong PH, *et al.* Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. *Ann Rheum Dis* 2015;74:408–14.
17. Calasan MB, den Boer E, de Rotte MC, *et al.* Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. *Ann Rheum Dis* 2015;74:402–7.
18. Aletaha D, Neogi T, Silman AJ, *et al.* 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569–81.
19. van Gestel AM, Prevoo ML, van 't Hof MA, *et al.* Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 1996;39:34–40.
20. van der Heijde DM, van 't Hof M, van Riel PL, *et al.* Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993;20:579–81.
21. Dervieux T, Orentas LD, Marcelletti J, *et al.* HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. *Clin Chem* 2003;49:1632–41.
22. Murosaki T, Nagatani K, Sato T, *et al.* Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis. *Mod Rheumatol* 2016. [Epub ahead of print 20 Jul 2016]. doi: 10.1080/14397595.2016.1208137
23. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. *Rheumatology (Oxford)* 2010;49:2337–45.
24. Stamp LK, O'Donnell JL, Chapman PT, *et al.* Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. *Arthritis Rheum* 2010;62:359–68.
25. Becker ML, Gaedigk R, van Haandel L, *et al.* The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. *Arthritis Rheum* 2011;63:276–85.
26. Brooks AJ, Begg EJ, Zhang M, *et al.* Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. *Ther Drug Monit* 2007;29:619–25.
27. Atsumi T, Yamamoto K, Takeuchi T, *et al.* The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. *Ann Rheum Dis* 2016;75:75–83.
28. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. *Pharmacogenomics* 2008;9:439–51.
29. den Boer E, de Rotte MC, Pluijm SM, *et al.* Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. *J Rheumatol* 2014;41:2167–78.
30. Ranganathan P, Culverhouse R, Marsh S, *et al.* Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. *J Rheumatol* 2008;35:572–9.